Clinical Trial

Intermittent Erector Spinae Plane Block Via Subcutaneous Port for Cancer Pain

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Cancer-related pain is a common and challenging problem in patients with lung cancer, often requiring long-term pain management. Conventional pain treatments, including systemic medications, may not provide adequate relief or may cause significant side effects. The erector spinae plane (ESP) block is a regional anesthesia technique that can help reduce pain by delivering local anesthetic near the nerves supplying the chest wall. This study aims to evaluate the effectiveness and safety of intermittent ESP block administered through a subcutaneous port for controlling cancer-related pain in patients with lung cancer. Eligible patients with lung cancer and moderate to severe pain will receive intermittent ESP block injections via a subcutaneous port as part of their pain management plan. Pain intensity, analgesic requirements, and potential side effects will be assessed over time. The results of this study may help determine whether intermittent ESP block via a subcutaneous port is a useful and feasible option for improving pain control and quality of life in patients with lung cancer.
Trial Details
NCT Number NCT07396558
Lead Sponsor Hanoi Medical University
Conditions Cancer Pain, Erector Spinae Plane Block
Enrollment 180 participants
Start Date 2026-03-01
Primary Completion 2027-09-01 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-09